Richard Decker Ginsburg, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Athletic Injuries | 3 | 2023 | 1163 | 0.230 |
Why?
|
| Sports | 1 | 2023 | 681 | 0.140 |
Why?
|
| Occupational Medicine | 1 | 2013 | 113 | 0.110 |
Why?
|
| Art | 1 | 2013 | 65 | 0.110 |
Why?
|
| Sports Medicine | 1 | 2013 | 233 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2188 | 0.070 |
Why?
|
| Brain Concussion | 1 | 2016 | 1338 | 0.060 |
Why?
|
| Occupational Diseases | 1 | 2013 | 1481 | 0.060 |
Why?
|
| Health Policy | 1 | 2016 | 2648 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 3896 | 0.050 |
Why?
|
| Health Promotion | 1 | 2013 | 2189 | 0.050 |
Why?
|
| Pheochromocytoma | 3 | 1988 | 325 | 0.050 |
Why?
|
| Athletes | 1 | 2023 | 1098 | 0.030 |
Why?
|
| Cardiomyopathies | 3 | 1993 | 1897 | 0.030 |
Why?
|
| Diltiazem | 1 | 1993 | 131 | 0.030 |
Why?
|
| Receptors, Adrenergic, alpha | 2 | 1993 | 145 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 1987 | 728 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1993 | 688 | 0.020 |
Why?
|
| Epinephrine | 1 | 1993 | 763 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 603 | 0.020 |
Why?
|
| Mental Health | 1 | 2023 | 3091 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1987 | 172 | 0.020 |
Why?
|
| Massachusetts | 1 | 2016 | 8593 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1986 | 595 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8434 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1987 | 1215 | 0.010 |
Why?
|
| Myocardial Contraction | 3 | 1993 | 1502 | 0.010 |
Why?
|
| Phenoxybenzamine | 2 | 1987 | 54 | 0.010 |
Why?
|
| Phentolamine | 2 | 1987 | 99 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1988 | 2130 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 25177 | 0.010 |
Why?
|
| Endomyocardial Fibrosis | 1 | 1993 | 39 | 0.010 |
Why?
|
| Rats | 4 | 1993 | 23680 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1993 | 237 | 0.010 |
Why?
|
| Humans | 3 | 2023 | 746044 | 0.010 |
Why?
|
| Calcium Channels | 1 | 1993 | 617 | 0.010 |
Why?
|
| Child | 1 | 2016 | 78456 | 0.000 |
Why?
|
| Adolescent | 1 | 2016 | 86202 | 0.000 |
Why?
|
| Organ Size | 1 | 1993 | 2239 | 0.000 |
Why?
|
| Myocardium | 2 | 1993 | 4639 | 0.000 |
Why?
|
| Hydralazine | 1 | 1987 | 35 | 0.000 |
Why?
|
| Timolol | 1 | 1987 | 52 | 0.000 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 1986 | 58 | 0.000 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1986 | 66 | 0.000 |
Why?
|
| Catecholamines | 1 | 1988 | 380 | 0.000 |
Why?
|
| Hypertrophy | 1 | 1988 | 558 | 0.000 |
Why?
|
| United States | 1 | 2013 | 70383 | 0.000 |
Why?
|
| Norepinephrine | 1 | 1987 | 881 | 0.000 |
Why?
|
| Male | 4 | 2016 | 351093 | 0.000 |
Why?
|
| Myocardial Ischemia | 1 | 1993 | 2142 | 0.000 |
Why?
|
| Body Weight | 1 | 1993 | 4590 | 0.000 |
Why?
|
| Middle Aged | 1 | 2016 | 214412 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 8125 | 0.000 |
Why?
|
| Adult | 1 | 2016 | 214958 | 0.000 |
Why?
|
| Blood Pressure | 2 | 1988 | 8404 | 0.000 |
Why?
|
| Heart Ventricles | 1 | 1993 | 3772 | 0.000 |
Why?
|
| Female | 3 | 2016 | 382109 | 0.000 |
Why?
|
| Heart | 1 | 1993 | 4361 | 0.000 |
Why?
|
| Aorta | 1 | 1986 | 2027 | 0.000 |
Why?
|
| Animals | 4 | 1993 | 166331 | 0.000 |
Why?
|
| Heart Rate | 1 | 1987 | 4039 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1988 | 17834 | 0.000 |
Why?
|
| Hypertension | 1 | 1987 | 8358 | 0.000 |
Why?
|